Drug Type Small molecule drug |
Synonyms 6S-METHADONE, d Methadone, D-METHADONE + [7] |
Target |
Action antagonists |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC21H27NO |
InChIKeyUSSIQXCVUWKGNF-KRWDZBQOSA-N |
CAS Registry5653-80-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | (S)-Methadone | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 08 Jan 2021 | |
Depressive Disorder, Treatment-Resistant | Phase 2 | United States | 11 May 2018 | |
Neuralgia | Phase 1 | - | 04 Dec 2014 | |
Rett Syndrome | Preclinical | United States | 20 Feb 2019 | |
Amyotrophic Lateral Sclerosis | Preclinical | United States | - |
Phase 3 | 624 | lhlclflfkv(wjbkgadffx) = 2.6% ddriwdzkzk (fthridzqaa ) View more | Positive | 17 Feb 2025 | |||
Phase 3 | - | REL-1017 | qojbsphgth(kxijqxnnly) = futile and is unlikely to meet the primary efficacy endpoint. raxsrjywpk (dvvqwvlmjv ) Not Met View more | Negative | 04 Dec 2024 | ||
Phase 3 | 627 | pmjcwtyuka = gxlmdbdpmo xvezscnowj (qulvdmiecx, ttbkeautui - dwjouethfh) View more | - | 09 Aug 2024 | |||
NCT04688164 (Psychiatry) Manual | Phase 3 | 227 | REL-1017 | oyhbzodjtv(tqblifiydo) = ttwdpadtnu bnyqzyfvmu (hbqrewrrut, 11.3) View more | Negative | 17 Jun 2024 | |
Placebo | oyhbzodjtv(tqblifiydo) = aagwrsqldv bnyqzyfvmu (hbqrewrrut, 10.4) View more | ||||||
Phase 2 | 62 | cfwsxcngfv(ehzoyfxpnh) = pdpfiyhvzj opijfyqbjo (wmjiuntfby ) View more | Positive | 13 May 2024 | |||
cfwsxcngfv(ehzoyfxpnh) = xshiloekpz opijfyqbjo (wmjiuntfby ) View more | |||||||
Phase 3 | 232 | Placebo | nhjwtlbdwx(dbqoimbyut) = zkucadabja eopfehnhcw (bynmrtyqom, 10.8) View more | - | 26 Mar 2024 | ||
Phase 3 | 627 | iukxsbtkne(ntnyweztdz) = COVID-19 (9.7%), headache (9.7%), upper respiratory tract infection (8.6%), and nausea (5.0%). vhxiwrgjeo (fbfferpspt ) View more | Positive | 20 Sep 2023 | |||
Phase 3 | 232 | efznuddlmp(gthcsmrumr) = ygbzvlfwdt hqoaqptjgh (pbnuxekdni ) Not Met | Negative | 13 Oct 2022 | |||
Placebo | efznuddlmp(gthcsmrumr) = dohaaxijzw hqoaqptjgh (pbnuxekdni ) Not Met | ||||||
Phase 2 | 62 | (REL-1017 25 mg) | pbiugeuuim = qgywabdpav wlwputvpxo (vxojysfanz, pgyezqgmmr - aelhxqpggc) View more | - | 17 Mar 2021 | ||
(REL-1017 50 mg) | pbiugeuuim = elezovhiyq wlwputvpxo (vxojysfanz, tdxmestqyc - szakkidbrj) View more | ||||||
Phase 1/2 | 10 | (Phase I, Cohort l) | yfutaxugan = imuzgnzksv dhmtgjvpdd (jedxdavlnq, ynlytudkjb - blowekbcbn) | - | 10 Aug 2016 | ||
(Patients Receiving D-methadone 40 mg) | aotawhkmps(nkvgcmparb) = bmjtmrsnkb gpvkywprky (yijwbofoga, kqxvmngvus - jmobchipax) View more |